Last reviewed · How we verify
NCT04593914: CASP-ORL
A Novel Skin Barrier Protectant for Acute Radiodermatitis
NA trial testing Cavilon Advanced Skin Protectant in Radiodermatitis. Withdrawn.
1 September 2021
Quick facts
| Lead sponsor | Jessa Hospital |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 September 2020 |
| Primary completion | 1 September 2021 |
| Estimated completion | 1 October 2021 |
| Sites | 2 locations across Belgium |
Drugs / interventions tested
- Cavilon Advanced Skin Protectant
Conditions studied
- Radiodermatitis — all drugs for Radiodermatitis →
- Radiation Toxicity — all drugs for Radiation Toxicity →
- Radiation Dermatitis — all drugs for Radiation Dermatitis →
- Skin Diseases — all drugs for Skin Diseases →
Sponsor
Jessa Hospital
Who can join
Adults 18 to 100, any sex, with Radiodermatitis or Radiation Toxicity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute radiodermatitis (ARD) is a distressing and painful skin reaction that occurs in 95% of the patients undergoing radiotherapy (RT). To date, there is still no general approved guideline for the prevention and management of acute radiodermatitis. The 3M™ Cavilon™ Advanced Skin Protectant is a novel skin barrier protectant that acts as a physical barrier against abrasion, moisture, and irritants. Moreover, it enables an environment for wound healing. The aim of this study is to evaluate the effectiveness of 3M™ Cavilon™ Advanced Skin Protectant in the prevention and management of ARD in patients with head and neck cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04593914
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cavilon Advanced Skin Protectant
Trials testing the same drug.
- NCT03298113 — Comparative Study to Assess an Advanced Skin Protectant in the Management of Incontinence-associated Dermatitis · NA · terminated
Other recruiting trials for Radiodermatitis
Currently open trials in the same condition.
- NCT07029178 — Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis · Phase 2 · recruiting
Other Jessa Hospital trials
Trials by the same sponsor.
- NCT07483775 — Feasibility and Health-economic Evaluation of Remote Clinical Monitoring Enabling Same-day Discharge After Bariatric Sur · NA · not yet recruiting
- NCT06881602 — Remote Clinical Monitoring After Robotic Distal Pancreatectomy · NA · not yet recruiting
- NCT07010055 — Using Digital Health in a Postoperative Setting After Major Surgery: Semi-structured Interview Study · NA · not yet recruiting
- NCT07010081 — Using Digital Health in a Postoperative Setting After Major Surgery: Survey Study · NA · recruiting
- NCT07482267 — Evaluation of Patients Suffering From Polytrauma Admitted to the ICU · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04593914 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jessa Hospital
- Last refreshed: 3 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04593914.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing